hero image

Biogen to Report Third Quarter 2017 Financial Results on October 24, 2017

September 26, 2017 News Release

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Inc. (NASDAQ:BIIB) today announced it will report third quarter 2017 financial results on Tuesday, October 24, 2017, before the financial markets open.

Following the release of the financials, the Company will host a live webcast with Biogen management from 8:30-9:30 am ET. To access the live webcast, please go to the investor relations section of Biogen’s website at www.biogen.com/investors. Following the live webcast, an archived version of the call will be available at the same URL.

About Biogen 
Through cutting-edge science and medicine, Biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics. For more information, please visit www.biogen.com. Follow us on social media – TwitterLinkedInFacebookYouTube.

Contact:

Biogen
Karen Jewell, 781-464-2442
Investor Relations

$Cashtags

$BIIB

thumb
April 25, 2024
Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®

CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE™ to the reference product ROACTEMRA ® CAMBRIDGE, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Committee for Medicinal Products for Human

thumb
April 24, 2024
Biogen Reports First Quarter 2024 Results